The Future Investor with Albert Anthony is a new series of curated research articles on the Seeking Alpha platform, focusing on growing a diversified portfolio and unlocking future drivers of performance.Albert Anthony is the pen name of a contributing analyst who has covered over +200 stocks on this platform since 2023, growing to over 1.07K followers. Based on this new article series, he is also working on a new book on Amazon to be called The Future Investor: Growing a Diversified Portfolio (2025 edition ...

Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer SymposiumBOSTON and BURLINGTON, N.C., Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first and only end-to-end, actionable cancer platform, announced today it has been selected to present the results of a biomarker awareness study, conducted with Labcorp, a global leader of innovative and comprehensive laboratory services, at the prestigious 2024 San Antonio Breast Cancer Symposium (SA ...

Julia Wang Named Chief Financial Officer Beginning December 2, 2024BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April ...

Labcorp Holdings Inc. (LH) , or Labcorp, is positioning itself for sustained growth with a series of strategic acquisitions and partnerships. With a growing emphasis on cell and gene therapy, the company aims to become a preferred development lab by leveraging its drug development expertise, scientific prowess and pharma relationships. The LaunchPad initiative also nears its targeted goal, which is highly promising. However, adverse macroeconomic impacts and currency fluctuations may dent the company’s grow ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 1-11353 LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 99-2588107 (State or other juri ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.50 in the third quarter of 2024. The figure rose 3.6% from the year-ago level.The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line beat the Zacks Consensus Estimate by 0.6%.On a GAAP basis, EPS in the third quarter was $2.00, up 5.2% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Foll ...

For the quarter ended September 2024, Labcorp (LH) reported revenue of $3.28 billion, up 7.4% over the same period last year. EPS came in at $3.50, compared to $3.38 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.26 billion, representing a surprise of +0.64%. The company delivered an EPS surprise of +0.57%, with the consensus EPS estimate being $3.48.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...

Labcorp (LH) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $3.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.57%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $3.78 per share when it actually produced earnings of $3.94, delivering a surprise of 4.23%.Over the last four quarters, the ...

Revenue and Financial Performance - Revenue for Q3 2024 increased to $3.28 billion, up 7.4% from $3.06 billion in Q3 2023[1][6] - Diagnostics Laboratories segment revenue increased 8.9% to $2.55 billion in Q3 2024, up from $2.34 billion in Q3 2023[10] - Biopharma Laboratory Services segment revenue grew 2.6% to $737.7 million in Q3 2024, compared to $719.1 million in Q3 2023[14] - Revenue for the nine months ended September 30, 2024, was $9,679.5 million, compared to $9,128.3 million for the same period in 2023[26] - Diagnostics Laboratories revenues increased to $2,553.5 million in Q3 2024, up from $2,344.7 million in Q3 2023, representing an 8.9% growth[30] - Biopharma Laboratory Services revenues grew to $737.7 million in Q3 2024, compared to $719.1 million in Q3 2023, a 2.6% increase[30] - Consolidated revenues for Q3 2024 reached $3,282.0 million, up 7.4% from $3,056.8 million in Q3 2023[30] Earnings and Profitability - Adjusted EPS for Q3 2024 was $3.50, compared to $3.38 in Q3 2023[1][7] - Net earnings attributable to Labcorp Holdings Inc. for the nine months ended September 30, 2024, were $602.6 million, compared to $585.1 million for the same period in 2023[26] - Diluted earnings per common share for the nine months ended September 30, 2024, were $7.13, compared to $6.63 for the same period in 2023[26] - Adjusted operating income for Diagnostics Laboratories was $387.4 million in Q3 2024, slightly up from $386.3 million in Q3 2023[30] - Biopharma Laboratory Services adjusted operating income rose to $120.9 million in Q3 2024, an 11.0% increase from $109.0 million in Q3 2023[30] - Consolidated adjusted operating income for Q3 2024 was $441.1 million, compared to $423.9 million in Q3 2023, a 4.1% growth[30] - Adjusted net income for Q3 2024 was $295.7 million, slightly up from $293.7 million in Q3 2023[32] Cash Flow and Financial Position - Free Cash Flow for Q3 2024 was $162 million, down from $171 million in Q3 2023[1][8] - Labcorp's cash balance at the end of Q3 2024 was $1.52 billion, with total debt of $6.75 billion[9] - Net cash provided by operating activities for the nine months ended September 2024 was $808.6 million, compared to $748.1 million in the same period of 2023[29] - Cash and cash equivalents surged to $1,517.3 million in September 2024, up from $536.8 million in December 2023, driven by strong operating cash flows[28][29] - Long-term debt increased to $5,352.1 million in September 2024 from $4,054.7 million in December 2023, primarily due to the issuance of senior notes[28][29] - Retained earnings grew to $8,275.8 million in September 2024 from $7,888.2 million in December 2023, reflecting strong earnings performance[28] - Accounts receivable increased to $2,058.5 million in September 2024 from $1,913.3 million in December 2023, indicating higher revenue generation[28] Guidance and Future Outlook - Updated Full-Year 2024 Revenue guidance range is 6.6% to 7.3%, with Adjusted EPS range of $14.30 to $14.70[1] - Labcorp Enterprise revenue for 2023 was $12.2 billion, with 2024 guidance ranging from 6.6% to 7.3% growth[17] - Diagnostics Laboratories revenue for 2023 was $9.4 billion, with 2024 guidance ranging from 7.2% to 7.8% growth[17] - Biopharma Laboratory Services revenue for 2023 was $2.8 billion, with 2024 guidance ranging from 4.7% to 5.6% growth[17] - Adjusted EPS for 2023 was $13.56, with 2024 guidance ranging from $14.30 to $14.70[17] - Free Cash Flow from continuing operations for 2023 was $0.89 billion, with 2024 guidance ranging from $0.85 to $0.98 billion[17] Acquisitions and Investments - Labcorp announced or completed five acquisitions/agreements, including Ballad Health's outreach lab services and Invitae's assets[3] - Labcorp invested $458.1 million in acquisitions during Q3 2024 and paid $60.5 million in dividends[9] - Acquisition of businesses, net of cash acquired, totaled $751.2 million for the nine months ended September 2024, compared to $516.7 million in the same period of 2023[29] - Capital expenditures for the nine months ended September 2024 were $377.8 million, up from $286.4 million in the same period of 2023[29] Operational and Strategic Developments - Labcorp expanded its collaboration with Ultima Genomics for whole genome sequencing and received FDA authorization for PGDx elio plasma focus Dx[4] - Labcorp supported 84% of new drugs and therapeutic products approved by the FDA in 2023[22] - Labcorp performed over 600 million tests for patients worldwide in 2023[22] Operating Margins - Adjusted operating margin for Diagnostics Laboratories decreased to 15.2% in Q3 2024 from 16.5% in Q3 2023[30] - Biopharma Laboratory Services adjusted operating margin improved to 16.4% in Q3 2024, up from 15.2% in Q3 2023[30] - Consolidated adjusted operating margin declined to 13.4% in Q3 2024 from 13.9% in Q3 2023[30] Dividends and Shareholder Returns - Dividends paid for the nine months ended September 2024 were $183.0 million, slightly lower than $192.9 million in the same period of 2023[29] - Labcorp paid $60.5 million in dividends during Q3 2024[9]

Updates Full-Year GuidanceResults from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounc ...